We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

171 hedge funds and large institutions have $1.59B invested in Amylyx Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 53 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

503% more call options, than puts

Call options by funds: $9.02M | Put options by funds: $1.5M

17% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 53

17% more capital invested

Capital invested by funds: $1.36B → $1.59B (+$230M)

1.02% more ownership

Funds ownership: 102.24% → 103.27% (+1%)

4% less funds holding

Funds holding: 179 → 171 (-8)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

19% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 36

Holders
171
Holders Change
-8
Holders Change %
-4.47%
% of All Funds
2.1%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.06%
New
29
Increased
62
Reduced
53
Closed
36
Calls
$9.02M
Puts
$1.5M
Net Calls
+$7.52M
Net Calls Change
+$2.34M

Top Buyers

1
SL
Siren LLC
Connecticut
+$17.3M
2
Franklin Resources
Franklin Resources
California
+$14.9M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11M
4
Barclays
Barclays
United Kingdom
+$9.52M
5
JAM
Jupiter Asset Management
United Kingdom
+$8.12M

Top Sellers

1
SI
Sofinnova Investments
California
-$6.37M
2
SCM
Silverarc Capital Management
Massachusetts
-$6.12M
3
Ameriprise
Ameriprise
Minnesota
-$6.07M
4
PSC
Patient Square Capital
California
-$4.23M
5
NCM
Nantahala Capital Management
Connecticut
-$4.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
76
Walleye Capital
New York
$858K +$787K +55,971 +975%
Russell Investments Group
77
Russell Investments Group
United Kingdom
$825K -$85.7K -6,092 -9%
Legal & General Group
78
Legal & General Group
United Kingdom
$775K -$237K -16,839 -23%
CCIA
79
Campbell & Co Investment Adviser
Maryland
$756K -$342K -24,341 -31%
EI
80
EAM Investors
California
$740K – – –
MIM
81
MetLife Investment Management
New Jersey
$717K +$27.2K +1,933 +4%
MS
82
Maven Securities
Jersey
$695K +$703K +50,000 New
N
83
Numerai
California
$675K -$902K -64,095 -57%
VGA
84
Vanguard Global Advisers
Pennsylvania
$665K +$673K +47,851 New
VAM
85
Vanguard Asset Management
$602K +$609K +43,283 New
Mirae Asset Global ETFs Holdings
86
Mirae Asset Global ETFs Holdings
Hong Kong
$591K +$19.5K +1,387 +3%
Zurich Cantonal Bank
87
Zurich Cantonal Bank
Switzerland
$567K +$574K +40,790 New
Susquehanna International Group
88
Susquehanna International Group
Pennsylvania
$553K -$409K -29,090 -42%
Manulife (Manufacturers Life Insurance)
89
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$539K +$166K +11,793 +44%
OF
90
Optimize Financial
California
$445K +$450K +32,001 New
Citigroup
91
Citigroup
New York
$442K -$87.9K -6,250 -16%
Tudor Investment Corp
92
Tudor Investment Corp
Connecticut
$436K +$126K +8,932 +40%
AQR Capital Management
93
AQR Capital Management
Connecticut
$404K +$17.5K +1,242 +4%
IQI
94
Integrated Quantitative Investments
Washington
$379K – – –
GC
95
Guggenheim Capital
Illinois
$355K +$3.8K +270 +1%
IIM
96
INTECH Investment Management
Florida
$346K -$99.7K -7,085 -22%
VPIM
97
Vanguard Personalized Indexing Management
California
$335K +$45.5K +3,232 +16%
PFSRSONJ
98
Police & Firemen's Retirement System of New Jersey
New Jersey
$330K – – –
State of New Jersey Common Pension Fund D
99
State of New Jersey Common Pension Fund D
New Jersey
$313K +$317K +22,519 New
New York State Common Retirement Fund
100
New York State Common Retirement Fund
New York
$304K – – –
2 3
4
5 6

AMLX Hedge Fund Activity: Q1 2026 in Review

171 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2026, worth a combined $1.59B — up 17% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of AMLX and 29 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 62 added.

The largest buyer was Siren LLC, opening a new position worth an estimated $17.3M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $6.37M sold.

  • 171 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2026, down from 179 in Q4 2025.
  • Funds reported $1.59B of Amylyx Pharmaceuticals stock for Q1 2026, up 17% quarter-over-quarter.
  • 29 funds opened new Amylyx Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of -7 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q1 2026 was Siren LLC, an estimated $17.3M added.
  • The largest Amylyx Pharmaceuticals seller in Q1 2026 was Sofinnova Investments, an estimated $6.37M sold.

Based on aggregated 13F filings for Q1 2026.